

## CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE .....	7
1. Background.....	9
2. Objective and Scope .....	9
3. Selection of Topics for Monographs .....	10
4. Data for Monographs .....	11
5. The Working Group .....	11
6. Working Procedures .....	11
7. Exposure Data.....	12
8. Studies of Cancer in Humans .....	14
9. Studies of Cancer in Experimental Animals.....	17
10. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	20
11. Summary of Data Reported .....	22
12. Evaluation .....	23
13. References.....	28
GENERAL REMARKS ON THE SUBSTANCES CONSIDERED .....	33
THE MONOGRAPHS.....	35
<b>Metallic Cobalt Particles (with or without Tungsten Carbide)</b> .....	37
1. Exposure Data.....	39
1.1 Chemical and physical data .....	39
1.1.1 Nomenclature .....	39
1.1.2 Molecular formulae and relative molecular mass .....	40
1.1.3 Chemical and physical properties of the pure substance .....	40
1.1.4 Technical products and impurities .....	40
1.1.5 Analysis .....	41
(a) Biological monitoring .....	41
(b) Analytical methods for workplace air and biological monitoring .....	41
(c) Reference values for occupationally non-exposed populations.....	41

1.2	Production and use .....	48
1.2.1	Production .....	48
	(a) Cobalt .....	48
	(b) Metallic carbides .....	49
	(c) Hard metals .....	52
	(d) Cobalt alloys .....	53
1.2.2	Use .....	53
1.3	Occurrence and exposure .....	55
1.3.1	Natural occurrence .....	55
1.3.2	Occupational exposure .....	55
	(a) Hard-metal production and use .....	56
	(b) Cobalt-containing diamond tooling .....	60
	(c) Alloys containing cobalt .....	62
	(d) Cobalt pigments .....	62
	(e) Production of cobalt metal and cobalt salts .....	63
	(f) Other exposures .....	64
1.3.3	Environmental exposure .....	64
	(a) Air .....	64
	(b) Water and sediments .....	64
	(c) Soils and plants .....	64
	(d) Foods and beverages .....	65
1.4	Regulations and guidelines .....	65
2.	Studies of Cancer in Humans .....	65
2.1	Hard-metal industry .....	65
2.2	Cobalt production industry .....	73
2.3	Other cobalt compounds .....	73
3.	Studies of Cancer in Experimental Animals.....	74
3.1	Inhalation exposure .....	74
	3.1.1 Mouse .....	74
	3.1.2 Rat.....	75
3.2	Intratracheal instillation .....	78
	Rat .....	78
3.3	Intramuscular injection .....	79
	Rat .....	79
3.4	Intramuscular implantation .....	80
	3.4.1 Rat.....	80
	3.4.2 Guinea-pig.....	80
3.5	Subcutaneous implantation .....	80
	Rat .....	80
3.6	Intra-osseous implantation .....	80
	3.6.1 Rat.....	80
	3.6.2 Rabbit .....	81

3.7	Intraperitoneal injection .....	81
	Rat .....	81
3.8	Intrarenal administration .....	81
	Rat .....	81
3.9	Intrathoracic injection .....	82
	Rat .....	82
4.	Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	82
4.1	Deposition, retention, clearance and metabolism .....	82
4.1.1	Humans .....	83
(a)	Deposition and retention .....	83
(b)	Intake and absorption .....	83
(c)	Excretion .....	85
4.1.2	Experimental systems .....	85
(a)	In-vivo studies .....	85
(b)	In-vitro studies .....	86
4.2	Toxic effects .....	87
4.2.1	Humans .....	87
(a)	Dermal effects .....	87
(b)	Respiratory effects .....	88
(i)	Bronchial asthma .....	88
(ii)	Hard-metal lung disease .....	88
(c)	Extrapulmonary effects .....	93
4.2.2	Experimental systems .....	93
(a)	Cobalt metal, hard metals and other alloys .....	93
(i)	Inflammation and fibrosis: in-vivo studies .....	93
(ii)	Cytotoxicity: in-vitro studies .....	97
(iii)	Biochemical effects .....	99
(b)	Other relevant cobalt compounds .....	101
(i)	Inflammation and fibrosis: in-vivo studies .....	101
(ii)	Cytotoxicity: in-vitro studies .....	102
(iii)	Biochemical effects .....	103
(iv)	Other effects .....	104
4.3	Reproductive and developmental effects .....	104
4.4	Genetic and related effects .....	105
4.4.1	Humans .....	105
(a)	Sister chromatid exchange .....	105
(b)	Micronuclei, DNA damage .....	107
4.4.2	Experimental systems .....	108
(a)	Metallic cobalt .....	108
(b)	Hard-metal particles .....	124

(c) Cobalt(II) chloride .....	125
(d) Other cobalt compounds .....	126
4.5 Mechanistic considerations .....	127
5. Summary of Data Reported and Evaluation.....	129
5.1 Exposure data .....	129
5.2 Human carcinogenicity data .....	130
5.3 Animal carcinogenicity data .....	131
5.4 Other relevant data .....	131
5.5 Evaluation .....	132
6. References.....	133

### **Introduction to the Monographs on Gallium Arsenide and Indium**

<b>Phosphide. Studies of Cancer in Humans .....</b>	<b>159</b>
---	------------

<b>Gallium Arsenide .....</b>	<b>163</b>
-------------------------------	------------

1. Exposure Data.....	163
1.1 Chemical and physical data .....	163
1.1.1 Nomenclature .....	163
1.1.2 Molecular formula and relative molecular mass .....	163
1.1.3 Chemical and physical properties of the pure substance .....	163
(a) Description.....	163
(b) Melting-point .....	163
(c) Density .....	163
(d) Solubility .....	163
(e) Stability .....	163
(f) Reactivity .....	163
1.1.4 Technical products and impurities .....	163
1.1.5 Analysis.....	164
(a) Determination of gallium.....	164
(b) Determination of arsenic .....	165
(i) Workplace air monitoring .....	165
(ii) Biological monitoring .....	165
(iii) Reference values for occupationally non-exposed populations .....	165
1.2 Production and use .....	166
1.2.1 Production.....	166
1.2.2 Use .....	168
1.3 Occurrence and exposure .....	169
1.3.1 Natural occurrence .....	169
1.3.2 Occupational exposure .....	169
1.4 Regulations and guidelines .....	171
2. Studies of Cancer in Humans .....	171

3. Studies of Cancer in Experimental Animals.....	173
3.1 Inhalation exposure .....	173
3.1.1 Mouse .....	173
3.1.2 Rat.....	173
3.2 Intratracheal instillation .....	175
Hamster .....	175
4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	176
4.1 Deposition, retention, clearance and metabolism .....	176
4.1.1 Humans .....	176
4.1.2 Experimental systems .....	176
(a) In-vitro solubility and dissolution in body fluids .....	176
(b) Respiratory system deposition, retention and clearance of gallium compounds .....	177
(i) Inhalation studies .....	177
(ii) Instillation studies with gallium arsenide .....	179
(c) Gastrointestinal exposure to gallium .....	180
(i) Oral and intraperitoneal studies .....	180
(ii) Intravenous injection of gallium-67: tracer studies ....	180
4.1.3 Data relevant to an evaluation of gallium arsenide as an arsenic compound .....	180
(a) Metabolism of the arsenic oxides .....	180
(b) Variation in arsenic methylation between species .....	181
4.2 Toxic effects .....	181
4.2.1 Humans .....	181
4.2.2 Experimental systems .....	182
(a) Gallium arsenide and gallium oxide .....	182
(i) Non-neoplastic and pre-neoplastic effects in the respiratory tract .....	182
(ii) Haematological effects.....	183
(iii) Immunological effects .....	183
(b) Other gallium compounds .....	184
(i) In vitro .....	184
(ii) In vivo .....	184
4.3 Reproductive and developmental effects .....	184
4.3.1 Humans .....	184
4.3.2 Animals.....	184
(a) Testicular function changes .....	184
(i) Gallium arsenide .....	184
(ii) Gallium oxide.....	185
(b) Effects on estrous cycles, gestation and foetal development .....	185

4.4	Genetic and related effects .....	186
4.5	Mechanistic considerations .....	186
5.	Summary of Data Reported and Evaluation.....	188
5.1	Exposure data .....	188
5.2	Human carcinogenicity data .....	188
5.3	Animal carcinogenicity data .....	188
5.4	Other relevant data .....	188
5.5	Evaluation .....	188
6.	References.....	190
<b>Indium Phosphide .....</b>		<b>197</b>
1.	Exposure Data.....	197
1.1	Chemical and physical data .....	197
1.1.1	Nomenclature .....	197
1.1.2	Molecular formula and relative molecular mass .....	197
1.1.3	Chemical and physical properties of the pure substance .....	197
	(a) Description .....	197
	(b) Melting-point .....	197
	(c) Density .....	197
	(d) Solubility .....	197
	(e) Reactivity .....	197
1.1.4	Technical products and impurities .....	197
1.1.5	Analysis.....	197
	(a) Workplace air monitoring .....	198
	(b) Biological monitoring .....	198
1.2	Production and use .....	198
1.2.1	Production.....	198
1.2.2	Use .....	199
1.3	Occurrence and exposure .....	200
1.3.1	Natural occurrence .....	200
1.3.2	Occupational exposure .....	200
1.3.3	Environmental exposure .....	200
1.4	Regulations and guidelines .....	201
2.	Studies of Cancer in Humans .....	202
3.	Studies of Cancer in Experimental Animals.....	202
3.1	Inhalation exposure .....	202
3.1.1	Mouse .....	202
3.1.2	Rat.....	206
3.1.3	Comparison of findings from the rat and mouse inhalation studies .....	210
3.2	Intratracheal instillation.....	211
	Hamster .....	211

4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	212
4.1 Deposition, retention, clearance and metabolism .....	212
4.1.1 Humans .....	212
4.1.2 Experimental systems .....	212
(a) Indium phosphide.....	212
(i) Inhalation studies in rats and mice .....	213
(ii) Intratracheal administration in rats .....	213
(iii) Intraperitoneal administration and gavage.....	214
(b) Other indium compounds.....	214
(i) Mice .....	214
(ii) Rats.....	214
4.2 Toxic effects .....	215
4.2.1 Humans .....	215
4.2.2 Experimental systems .....	215
(a) Indium phosphide.....	215
(b) Other indium compounds.....	216
4.3 Reproductive and developmental effects .....	217
4.3.1 Humans .....	217
4.3.2 Experimental systems .....	217
4.4 Genetic and related effects .....	218
4.5 Mechanistic considerations .....	218
5. Summary of Data Reported and Evaluation.....	219
5.1 Exposure data .....	219
5.2 Human carcinogenicity data .....	219
5.3 Animal carcinogenicity data .....	219
5.4 Other relevant data .....	219
5.5 Evaluation .....	220
6. References.....	221
<b>Vanadium Pentoxide .....</b>	<b>227</b>
1. Exposure Data.....	227
1.1 Chemical and physical data .....	227
1.1.1 Nomenclature .....	227
1.1.2 Empirical formula and relative molecular mass.....	227
1.1.3 Chemical and physical properties of the pure substance .....	227
(a) Description.....	227
(b) Boiling-point .....	227
(c) Melting-point .....	227
(d) Density .....	227
(e) Solubility .....	227
(f) Stability .....	230

1.1.4	Technical products and impurities .....	230
1.1.5	Analysis.....	230
	(a) Monitoring workplace and ambient air .....	230
	(b) Biological monitoring .....	231
	(i) Tissues suitable for biomonitoring of exposure.....	231
	(ii) Precautions during sampling and sample handling ....	231
	(iii) Analytical methods .....	231
	(iv) Reference values in occupationally non-exposed populations .....	233
1.2	Production and use .....	234
1.2.1	Production.....	234
1.2.2	Use .....	236
1.3	Occurrence and exposure .....	237
1.3.1	Natural occurrence .....	237
1.3.2	Occupational exposure .....	237
1.3.3	Environmental exposure .....	240
	(a) Air .....	240
	(i) Natural sources.....	240
	(ii) Anthropogenic sources.....	241
	(b) Water .....	242
	(c) Food .....	242
1.4	Regulations and guidelines .....	243
2.	Studies of Cancer in Humans .....	243
3.	Studies of Cancer in Experimental Animals.....	243
3.1	Inhalation exposure .....	243
3.1.1	Mouse .....	243
3.1.2	Rat.....	245
3.1.3	Comparison of findings from the rat and mouse inhalation studies .....	248
4.	Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	250
4.1	Deposition, retention, clearance and metabolism .....	250
4.1.1	Humans .....	251
4.1.2	Experimental systems .....	252
	(a) In-vivo studies .....	252
	(i) Inhalation studies .....	252
	(ii) Intratracheal instillation .....	254
	(iii) Oral administration .....	254
	(b) Cellular studies.....	255
4.2	Toxic effects .....	255
4.2.1	Humans .....	255
	(a) Studies with volunteers .....	255



(b)	Studies of workers exposed to vanadium .....	256
(c)	Environmental exposure .....	257
4.2.2	Experimental systems .....	258
(a)	In-vivo studies .....	258
(i)	General toxicity .....	258
(ii)	Respiratory effects .....	259
(iii)	Hepatic effects .....	262
(iv)	Renal effects .....	262
(v)	Nervous system effects .....	263
(vi)	Cardiovascular system effects .....	263
(vii)	Skeletal alterations .....	263
(viii)	Immunological effects .....	264
(ix)	Biochemical effects .....	264
(b)	In-vitro studies .....	264
(i)	Organ culture .....	264
(ii)	Cell culture .....	265
(iii)	Cell-free systems .....	266
4.3	Reproductive and developmental effects .....	267
4.3.1	Humans .....	267
4.3.2	Experimental systems .....	267
(a)	In-vivo studies .....	267
(i)	Toxicokinetics in pregnant animals .....	267
(ii)	Effects on reproductive organs and fertility .....	268
(iii)	Developmental effects .....	268
(b)	In-vitro studies .....	269
4.4	Genetic and related effects .....	270
4.4.1	Humans .....	270
4.4.2	Experimental systems .....	270
(a)	Biochemical assays .....	270
(b)	Mutagenicity .....	270
(i)	In-vitro studies .....	270
(ii)	In-vivo studies .....	275
(c)	Genetic changes in vanadium pentoxide-induced tumours .....	276
4.5	Mechanistic considerations .....	276
5.	Summary of Data Reported and Evaluation .....	276
5.1	Exposure data .....	276
5.2	Human carcinogenicity data .....	277
5.3	Animal carcinogenicity data .....	277
5.4	Other relevant data .....	277
5.5	Evaluation .....	278
6.	References .....	278

LIST OF ABBREVIATIONS USED IN THIS VOLUME .....293

SUPPLEMENTARY CORRIGENDA TO VOLUMES 1–86.....295

CUMULATIVE INDEX TO THE *MONOGRAPHS* SERIES.....297

## NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.